Heart failure & cardiomyopathiesCohort study

Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population

JAMA CardiolPublished

  • Population-based cohort study
  • UK Biobank
  • whole-exome sequencing

Authors' conclusion

This study found that approximately 1 in 1000 UKB participants were LP/P TTR variant carriers, exceeding previously reported prevalence.

Study context

Population
UK Biobank participants with whole-exome sequencing, ECG and CMR data, enrolled 2006–2010
Participants
469,789 participants
Exposure
TTR variant carriers vs non-carriers
  • LP/Pn = 473
  • Variant of unknown significancen = 91
Outcome
Prevalence of disease-causing TTR variants; associations with imaging/ECG traits, AF, conduction disease, HF and all-cause mortality
Follow-up
Median 12 (IQR, 11-13) years

Main finding

As reported in the abstract

Prevalence of LP/P TTR variants
GroupValueVal142IleEuropean ancestryAfrican ancestry
LP/P0.1%367 [77.6%]0.02% (105 of 444 243)4.3% (321 of 7533)
VUS0.02%

Observational data: associations, not effects.

Further findings

HF, conduction disease and all-cause mortality

ComparisonHR (95% CI)
LP/P · HF · adjusted Cox models2.68 (1.75–4.12)
LP/P · conduction disease · adjusted Cox models1.88 (1.25–2.83)
non-Val142Ile LP/P · all-cause mortality · adjusted Cox models1.98 (1.06–3.67)
OutcomeLP/PVariant of unknown significanceβ (95% CI)
LV mass indexed to body surface area4.66 (1.87–7.44)
PR interval (Val142Ile)18.34 (5.41–31.27)
Diagnostic codes compatible with cardiac or neurologic amyloidosis2.8%Not reported in the abstract

HF, conduction disease and all-cause mortality

VUS not associated with outcomes

Original publication

Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population. JAMA Cardiol. Published 1 November 2024. doi:10.1001/jamacardio.2024.2190

Summarised from the published abstract; every number is checked against it